文档介绍：26例慢性粒细胞白血病的临床分析
(作者:___________单位: ___________邮编: ___________)
【摘要】目的:结合病历分析各种治疗慢性粒细胞白血病(CML)药物的特点,寻找适合基层医院应用的治疗方法。方法:本组CML病人26人,男18例,女8例,根据国内采用的诊断标准明确诊断,分别应用羟基脲,马利兰,甲异靛及合用α干扰素治疗。结果:应用羟基脲治疗的患者中10例达血液学完全缓解,4例部分缓解,1例未缓解;应用马利兰治疗的有3例达到血液学完全缓解,2例部分缓解,1例未缓解;应用甲异靛治疗的2人均达部分缓解;加用α干扰素治疗的3人生存期3~10年。结论:今后在CML病人的治疗中,应以达到细胞遗传学缓解为治疗目标,在目前基层医院条件下,首选干扰素加化学药物治疗。
【关键词】慢性粒细胞白血病;治疗;羟基脲;α干扰素
Clinical Analyse on Treating 26 Chronic Myelogenous Leukemia
HUANG Weihong
Internal Department,Beijing Yanhua Phoenix Hospital, Beijing, 102425, China
【ABSTRACT】 Objective:To analyze the medicament features for treating all kinds of chronic myelogenous leukemia (CML), and seeks the therapeutic methods suitable for primary : 26 patients with CML are selected, among which 18 are male and 8 are to the domestic diagnosis standard, the patients are treated by using hydroxyurea, myleran, meisoindigo bined with αinterferon. Results: Among the patients treated by hydroxyurea,10 patients get plete remission, 4 patients get partial remission, 1 patient doesnt get remission; 3 patients treated by using myleran obtain plete remission, 2 patients are partial remission, and 1 patient doesnt get remission; 2 patients treated by meisoindigo all get partial remission; the lifetime of the three patients treated by adding αinterferon is 3~10 : In the therapy for CML patients, ics remission will be treating target. According to the condition of primary hospitals, bined with chemical medicines will be the preferred method in curing CML.
【KEY WORDS】 CML; Therapay; Hydroxyurea; αinterferon
慢性粒细胞白血病(CML)是累及造血系统干细胞系的恶性肿瘤疾病,其临床表现大多数病例起病缓慢,病程较长,发病年龄在21~40岁的人数最多。CML发病率占所有白血病的20%,其自然临床过程可以分为慢性期(2~6年),急变期(3~6月)以及两期之间的加速期(1~15年)三个阶段。自觉症状往往是乏力、低热、多汗或盗汗,体重减轻,脾脏肿大,少数病人有出血倾向。现对我院自1970~2002年间的26例慢粒白血病进行如下分析。
1 资料与方法
11 一般资料
本组26例患者,男18例,女8例;年龄平均42岁(24~75岁)。仅一例患者发病前有明确的苯中毒病史,其余患者均无高热、感染及确切的毒物质接触史。
12 临床表现
121 症状及体征
脾肿大达左肋下1~20cm不等,肝肿大达右肋下05~5cm不等,多数为2~3cm。腹股